Ocrelizumab for PPMS

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Barts-MS

Do you agree that the ocrelizumab trial results show that PPMS is modifiable?

Yes

Clear selection

Are the ocrelizumab trial results meaningful for pwPPMS?

Ocrelizumab will delay the need for using a wheelchair by about 4 years.

Yes

Clear selection

Do you think it is fair that only pwPPMS who can afford to pay privately should have access to ocrelizumab?

If ocrelizumab is not licensed by the EMA, or greenlighted by NICE, it will create a perverse situation were pwPPMS who can afford to pay for ocrelizumab privately will have access to the drug, whilst the majority of pwPPMS will not be treated.

Yes

Clear selection

What should be done to allow pwPPMS to access to ocrelizumab?

You can choose more than one option!

Ensure the EMA understands the unmet need and licenses ocrelizumab for PPMS

Ensure the payers and healthcare systems understand the unmet need and provide access to ocrelizumab for pwPPMS

Ask the MS Society and other stakeholders to make sure the EMA and Payers understand the unmet need on PPMS

Start a campaign to make the MS community aware how important this issue is for pwPPMS

Ask Roche to launch a compassionate access programme so pwPPMS can access ocrelizumab early

Ask Roche to explore ways to make ocrelizumab cost-effective for the treatment of PPMS

Arrange a PPMS protest to highlight the unmet need

Other:

What type of MS do you have?

CIS

RRMS

SPMS

PPMS

Clear selection

What country do you live in?

Disclaimer

No personal identifiers will be collected as part of this audit. By completing this survey you are consenting to the data you provide being analysed by Professor Giovannoni and the MS Team at Barts Health NHS Trust. Results of this audit will be analysed, written-up, presented to the Barts-MS team and may be submitted for publication.

Submit

Clear form

Never submit passwords through Google Forms.

Forms

This form was created inside of Gavin Giovannoni.